BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37890514)

  • 1. A Review of PARP-1 Inhibitors: Assessing Emerging Prospects and Tailoring Therapeutic Strategies.
    Ramesh S; Almeida SD; Hammigi S; Radhakrishna GK; Sireesha G; Panneerselvam T; Vellingiri S; Kunjiappan S; Ammunje DN; Pavadai P
    Drug Res (Stuttg); 2023 Nov; 73(9):491-505. PubMed ID: 37890514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications.
    Sodhi RK; Singh N; Jaggi AS
    Vascul Pharmacol; 2010; 53(3-4):77-87. PubMed ID: 20633699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying Direct Protein Targets of Poly-ADP-Ribose Polymerases (PARPs) Using Engineered PARP Variants-Orthogonal Nicotinamide Adenine Dinucleotide (NAD+) Analog Pairs.
    Carter-O'Connell I; Cohen MS
    Curr Protoc Chem Biol; 2015 Jun; 7(2):121-39. PubMed ID: 26344237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of protein poly(ADP-ribosyl)ation systems across all domains of life.
    Perina D; Mikoč A; Ahel J; Ćetković H; Žaja R; Ahel I
    DNA Repair (Amst); 2014 Nov; 23():4-16. PubMed ID: 24865146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose): PARadigms and PARadoxes.
    Bürkle A; Virág L
    Mol Aspects Med; 2013 Dec; 34(6):1046-65. PubMed ID: 23290998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
    Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity.
    Heer CD; Sanderson DJ; Voth LS; Alhammad YMO; Schmidt MS; Trammell SAJ; Perlman S; Cohen MS; Fehr AR; Brenner C
    J Biol Chem; 2020 Dec; 295(52):17986-17996. PubMed ID: 33051211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Clickable NAD
    Zhang L; Lin H
    Methods Mol Biol; 2017; 1608():95-109. PubMed ID: 28695506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
    Virág L
    Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.
    van Beek L; McClay É; Patel S; Schimpl M; Spagnolo L; Maia de Oliveira T
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation.
    Lu AZ; Abo R; Ren Y; Gui B; Mo JR; Blackwell D; Wigle T; Keilhack H; Niepel M
    Biochem Pharmacol; 2019 Sep; 167():97-106. PubMed ID: 31075269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical genetic methodologies for identifying protein substrates of PARPs.
    Rodriguez KM; Cohen MS
    Trends Biochem Sci; 2022 May; 47(5):390-402. PubMed ID: 34366182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of PARP and protein poly-ADP-ribosylation process in regulation of cell functions].
    Drel' VR; Shymans'kyĭ IO; Sybirna NO; Velykyĭ MM
    Ukr Biokhim Zh (1999); 2011; 83(6):5-34. PubMed ID: 22364016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARPs and the DNA damage response.
    Sousa FG; Matuo R; Soares DG; Escargueil AE; Henriques JA; Larsen AK; Saffi J
    Carcinogenesis; 2012 Aug; 33(8):1433-40. PubMed ID: 22431722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural inhibitors of poly(ADP-ribose) polymerase-1.
    Banasik M; Stedeford T; Strosznajder RP
    Mol Neurobiol; 2012 Aug; 46(1):55-63. PubMed ID: 22476980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics.
    Kirby IT; Cohen MS
    Curr Top Microbiol Immunol; 2019; 420():211-231. PubMed ID: 30242511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose) polymerase enzymes and the maintenance of genome integrity.
    Eisemann T; Pascal JM
    Cell Mol Life Sci; 2020 Jan; 77(1):19-33. PubMed ID: 31754726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The poly(ADP-ribose) polymerases (PARPs): new roles in intracellular transport.
    Abd Elmageed ZY; Naura AS; Errami Y; Zerfaoui M
    Cell Signal; 2012 Jan; 24(1):1-8. PubMed ID: 21840394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting and Quantifying pADPr In Vivo.
    Lamade AM; Chen Y; Johnson CJ; Bayır H; Clark RSB
    Methods Mol Biol; 2023; 2609():23-42. PubMed ID: 36515827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.